Objective

2

To observe the clinical efficacy and safety of Yucan Granules combined with losartan potassium tablets in treating diabetic kidney disease （DKD）.

Methods

2

Ninety DKD patients with qi deficiency and damp stasis syndrome were randomly divided into a treatment group （

n

=45） and a control group （

n

=45）. Besides conventional treatment， the treatment group received additional Yucan Granules and losartan potassium tablets， while the control group received Yucan placebo and losartan potassium tablets. Both groups were treated for 12 weeks. Clinical efficacy was observed， and the 24-hour urinary protein quantification， urine albumin to creatinine ratio （UACR）， and laboratory indicators ［serum creatinine （Scr）， blood urea nitrogen （BUN）， estimated glomerular filtration rate （eGFR）， total cholesterol （TC）， low-density lipoprotein （LDL）， C-reactive protein （CRP）， serum amyloid A （SAA）， and interleukin-6 （IL-6）］ were compared before and after treatment， along with a safety assessment.

Results

2

①Forty-four patients in both treatment and control groups completed the trial. ②The total clinical effective rate was 79.55% in the treatment group and 56.82% in the control group， and the total effective rate of traditional Chinese medicine syndromes was 86.36% and 72.73%， respectively， with statistically significant differences （

P

<

0.05）， indicating better efficacy in the treatment group. ③Intra-group comparisons before and after treatment showed reductions in 24-hour urinary protein quantification and UACR in both groups （

P

<

0.05）. Inter-group comparisons after treatment showed that 24-hour urinary protein quantification and UACR were lower in the treatment group （

P

<

0.05）. ④Both groups showed reductions in the levels of Scr， BUN， eGFR， TC， LDL， CRP， SAA

， and IL-6 after treatment （

P

<

0.05）； Inter-group comparisons after treatment showed that levels of Scr， TC， LDL， CRP， SAA， and IL-6 were lower in the treatment group compared to those in the control group （

P

<

0.05）. ⑤No significant adverse reactions were observed in either group during the trial.

Conclusions

2

The efficacy of Yucan Granules combined with losartan potassium tablets in treating diabetic kidney disease is satisfactory. The combined use of Yucan Granules and losartan potassium tablets can effectively improve urinary protein levels and systemic inflammation in patients with diabetic kidney disease， and slow disease progression with good safety.